Your browser doesn't support javascript.
loading
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
Hollnberger, Julius; Liu, Yang; Xu, Simin; Chang, Silvia; Martin, Ross; Manhas, Savrina; Aeschbacher, Thomas; Han, Bin; Yazdi, Tahmineh; May, Lindsey; Han, Dong; Shornikov, Alex; Flaherty, John; Manuilov, Dmitry; Suri, Vithika; Asselah, Tarik; Lampertico, Pietro; Wedemeyer, Heiner; Aleman, Soo; Richards, Christopher; Mateo, Roberto; Maiorova, Evguenia; Cihlar, Tomas; Mo, Hongmei; Urban, Stephan.
Afiliación
  • Hollnberger J; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany; German Center for Infection Research (DZIF), Heidelberg Partner Site, Heidelberg, Germany.
  • Liu Y; Gilead Sciences Inc., Foster City, California, USA. Electronic address: Yang.liu@gilead.com.
  • Xu S; Gilead Sciences Inc., Foster City, California, USA.
  • Chang S; Gilead Sciences Inc., Foster City, California, USA.
  • Martin R; Gilead Sciences Inc., Foster City, California, USA.
  • Manhas S; Gilead Sciences Inc., Foster City, California, USA.
  • Aeschbacher T; Gilead Sciences Inc., Foster City, California, USA.
  • Han B; Gilead Sciences Inc., Foster City, California, USA.
  • Yazdi T; Gilead Sciences Inc., Foster City, California, USA.
  • May L; Gilead Sciences Inc., Foster City, California, USA.
  • Han D; Gilead Sciences Inc., Foster City, California, USA.
  • Shornikov A; Gilead Sciences Inc., Foster City, California, USA.
  • Flaherty J; Gilead Sciences Inc., Foster City, California, USA.
  • Manuilov D; Gilead Sciences Inc., Foster City, California, USA.
  • Suri V; Gilead Sciences Inc., Foster City, California, USA.
  • Asselah T; Department of Hepatologi, Hôpital Beaujon, AP-HP, Université de Paris-Cité, INSERM UMR 1149, Clichy, France.
  • Lampertico P; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy; "A.M. e A. Migliavacca" Center for the Study of Liver Disease, Università degli Studi di Milano, Milan, Italy.
  • Wedemeyer H; Medizinische Hochschule, Hannover, Germany.
  • Aleman S; Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden.
  • Richards C; Gilead Sciences Inc., Foster City, California, USA.
  • Mateo R; Gilead Sciences Inc., Foster City, California, USA.
  • Maiorova E; Gilead Sciences Inc., Foster City, California, USA.
  • Cihlar T; Gilead Sciences Inc., Foster City, California, USA.
  • Mo H; Gilead Sciences Inc., Foster City, California, USA.
  • Urban S; Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany; German Center for Infection Research (DZIF), Heidelberg Partner Site, Heidelberg, Germany. Electronic address: Stephan.Urban@med.uni-heidelberg.de.
J Hepatol ; 79(3): 657-665, 2023 09.
Article en En | MEDLINE | ID: mdl-37120031
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Virus de la Hepatitis Delta Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Virus de la Hepatitis Delta Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania